SU2C establishes $3.25M head and neck cancer research team

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stand Up To Cancer announced the Stand Up To Cancer–Fanconi Anemia Research Fund–Farrah Fawcett Foundation Head and Neck Cancer Research Team, which will focus on new approaches to address head and neck squamous cell carcinoma, with an emphasis on cancers related to the human papillomavirus and Fanconi anemia.

The team has been awarded $3.25 million over three years to advance therapies, support new approaches, and improve patient outcomes for head and neck cancers. The team will receive $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation. The American Head and Neck Society and the Head and Neck Cancer Alliance also each provided $125,000 in support. 

Agata Smogorzewska, associate professor at The Rockefeller University, will lead the research team and Barbara Burtness, professor of medicine, interim associate director for diversity, equity and inclusion and co-leader, Developmental Therapeutics Program at Yale Cancer Center and Smilow Cancer Hospital, will serve as co-leader.

Table of Contents

YOU MAY BE INTERESTED IN

With growing evidence that molecular characterization of a tumor helps predict a patient’s prognosis and response to specific treatments, biomarker testing has been required or recommended for more than half of the 62 oncology drugs introduced over the past five years. However, health insurance policies don’t always cover tests, thus denying their clients access to precision medicine.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).

Login